COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00064090
Recruitment Status : Completed
First Posted : July 9, 2003
Last Update Posted : July 18, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more cancer cells by making them more sensitive to the drug.

PURPOSE: Phase I trial to study the effectiveness of combining cytarabine with 3-AP in treating patients who have relapsed or refractory hematologic cancer.

Condition or disease Intervention/treatment Phase
Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Drug: cytarabine Drug: triapine Phase 1

Detailed Description:


  • Determine the feasibility, tolerability, and toxic effects of 3-AP in combination with cytarabine in patients with hematologic malignancies.
  • Determine the maximum tolerated dose and phase II dose of cytarabine in this regimen in these patients.
  • Determine the biological effects of 3-AP and its interaction with cytarabine in these patients.

OUTLINE: This is a pilot, dose-escalation study of cytarabine.

Patients receive 3-AP IV over 6 hours followed by cytarabine IV over 18 hours on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a response may receive an additional course as consolidation therapy.

Cohorts of 3-6 patients receive escalating doses of cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 10 patients receive treatment at that dose.

PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Phase I Study of Triapine and Cytarabine in Patients With Hematologic Malignancies
Study Start Date : March 2003
Actual Primary Completion Date : September 2004
Actual Study Completion Date : January 2008

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of 1 of the following hematologic malignancies:

    • Acute myeloid leukemia
    • Acute lymphoblastic leukemia
    • Chronic myelogenous leukemia (CML)
    • CML in blast crisis
    • Chronic lymphocytic leukemia
    • High-risk* myelodysplastic syndromes, including the following:

      • Refractory anemia with excess blasts (RAEB)
      • RAEB in transformation
      • Chronic myelomonocytic leukemia NOTE: *High-risk myelodysplasia defined as having an International Performance Scoring System score of at least 1.5, based on adverse cytogenetics, greater than 10% blasts in marrow, and cytopenias in at least 2 lineages
  • Relapsed or refractory disease
  • Ineligible for higher priority protocols



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • More than 2 months


  • See Disease Characteristics


  • Bilirubin no greater than 2.0 mg/dL (unless considered due to malignancy)
  • ALT or AST no greater than 3 times upper limit of normal
  • Chronic hepatitis allowed


  • Creatinine no greater than 2.0 mg/dL (unless considered due to malignancy)


  • No myocardial infarction within the past 3 months
  • No symptomatic coronary artery disease
  • No arrhythmias (other than atrial fibrillation or flutter) requiring treatment
  • No uncontrolled congestive heart failure


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Concurrent infections under active treatment with and controlled by antibiotics allowed
  • No other concurrent life-threatening illness
  • No mental deficit or psychiatric history that would preclude giving informed consent or complying with protocol


Biologic therapy

  • At least 1 week since prior growth factors, including the following:

    • Epoetin alfa
    • Filgrastim (G-CSF)
    • Sargramostim (GM-CSF)
    • Interleukin-3
    • Interleukin-11
  • No concurrent anticancer immunotherapy


  • At least 72 hours since prior hydroxyurea
  • Recovered from prior chemotherapy
  • No other concurrent anticancer chemotherapy

Endocrine therapy

  • Not specified


  • At least 2 weeks since prior radiotherapy
  • No concurrent anticancer radiotherapy


  • Not specified


  • At least 3 weeks since prior myelosuppressive cytotoxic agents (in the absence of rapidly progressing disease)
  • At least 1 week since prior nonmyelosuppressive therapy
  • No other concurrent standard or investigational therapy for the malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00064090

Layout table for location information
United States, Texas
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030-4095
Sponsors and Collaborators
Vion Pharmaceuticals
Layout table for investigator information
Study Chair: Mario Sznol, MD Vion Pharmaceuticals
Layout table for additonal information Identifier: NCT00064090    
Other Study ID Numbers: VION-CLI-032
CDR0000306465 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: July 9, 2003    Key Record Dates
Last Update Posted: July 18, 2013
Last Verified: August 2008
Keywords provided by National Cancer Institute (NCI):
recurrent adult acute lymphoblastic leukemia
recurrent adult acute myeloid leukemia
blastic phase chronic myelogenous leukemia
refractory chronic lymphocytic leukemia
relapsing chronic myelogenous leukemia
chronic myelomonocytic leukemia
refractory anemia with excess blasts in transformation
refractory anemia with excess blasts
previously treated myelodysplastic syndromes
atypical chronic myeloid leukemia, BCR-ABL1 negative
myelodysplastic/myeloproliferative neoplasm, unclassifiable
adult acute myeloid leukemia with t(8;21)(q22;q22)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with t(15;17)(q22;q12)
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs